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This editorial refers to ‘Prognostic impact of a chronic
total occlusion in a non-infarct-related artery in patients
with ST-segment elevation myocardial infarction: 3-year
results from the HORIZONS-AMI trial’†, by
B.E. Claessen et al., on page 768
Chronic total occlusions (CTOs) are complete obstructions of
coronary arteries, described as ≥99% stenosis, of .3 months dur-
ation, and with poor or no antegrade blood flow, i.e. TIMI flow
grade 0–1. Patients with CTOs are frequently encountered in
interventional cardiology practice. It has been estimated that
one-third of patients with coronary artery disease requiring revas-
cularization have a CTO, and that 10–20% of lesions intended
for percutaneous revascularization are complete occlusions.1 In
stable coronary artery disease, the negative impact of a CTO has
been demonstrated. A New York State survey showed that incom-
plete percutaneous revascularization leaving untreated CTOs led
to higher 3-year mortality.2 In the setting of primary percutaneous
coronary intervention (pPCI) for ST-segment elevation myocardial
infarction (STEMI), previous studies have suggested that the
increased mortality observed in patients with multivessel disease
(MVD) was mainly driven by the presence of a CTO in a
non-infarct-related artery (IRA).3,4 Furthermore, STEMI patients
with a CTO in a non-IRA were found to have suboptimal reperfu-
sion more frequently, as shown by lower myocardial blush grades
and a lesser degree of ST-segment resolution following pPCI.5
Claessen et al.6 have retrospectively evaluated 3283 STEMI
patients undergoing pPCI within the HORIZONS-AMI trial and
confirmed the worse prognosis of patients with a CTO in a
non-IRA (n ¼ 283). Accordingly they report impaired markers of
reperfusion and increased early (0–30 days), late (30 days–3
years), and cumulative 3-year mortality in this specific group of
patients. Patients with MVD but no CTO (n ¼ 1477) had increased
early but not late mortality. The mechanism related to higher mor-
tality in STEMI patients with a non-IRA CTO is probably multifac-
torial. In the trial, patients with a non-IRA CTO achieved
suboptimal reperfusion following pPCI, as documented by less
frequent complete ST-segment resolution, post-procedural TIMI
grade 3 flow, and myocardial blush in the IRA territory. It is also
possible that patients with CTO in a non-IRA suffer larger myocar-
dial infarctions following IRA occlusion due to the extension of the
infarction beyond the territory normally supplied by the IRA fol-
lowing abrupt cessation or impairment of collateral flow. In the
study of Claessen et al., the peak creatine phosphokinase levels
tended to be higher in the CTO group, but were not significantly
different between patients with and without CTO of a non-IRA,
and additional studies are needed to prove the ‘impaired collateral
flow’ hypothesis.
The finding that the presence of a CTO in a non-IRA is asso-
ciated with worse adverse events raises the question of whether
revascularization of the CTO would lead to improved outcomes.
In stable patients, recanalization of a CTO in the presence of a
sizable viable territory has been associated with improvement in
symptoms, left ventricular (LV) function, and survival,8 but no
such data are available in the setting of pPCI for STEMI. While
this issue cannot be answered by the study of Claessen et al.,
there is indeed some evidence that the recanalization of a staged
non-IRA CTO may lead to improved outcomes. A retrospective
study by Yang et al. on 136 patients undergoing staged recanaliza-
tion of a non-IRA CTO 7–10 days following STEMI suggested a
beneficial clinical effect from the procedure.7 After adjustment
for possible confounders, successful recanalization of the CTO
was identified as an independent predictor for lower 2-year
cardiac mortality [hazard ratio (HR) ¼ 0.145, 95% confidence
interval (CI) 0.047–0.446, P ¼ 0.001] and major adverse cardiac
events (MACE)-free survival (HR ¼ 0.430, 95% CI 0.220–0.838,
P ¼ 0.013).7
It should be noted that current national guidelines do not rec-
ommend non-culprit lesion intervention during pPCI for STEMI
without cardiogenic shock or severe haemodynamic compromise.9
In fact, prior studies have shown that treatment of non-culprit
lesions during pPCI for STEMI in haemodynamically stable patients
was associated with increased post-procedural morbidity in the
absence of mortality benefit.10,11
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While the study by Yang et al.7 provides some preliminary
evidence for a strategy of staged PCI for a non-IRA CTO,
robust randomized trials are indicated to assess this approach
objectively. The decision to proceed with revascularization of
a non-IRA CTO following STEMI needs to take into account in-
dividual patient symptoms, the angiographic complexity of the
occlusion, LV function, and myocardial viability, as well as ischae-
mia in the CTO territory. Clinicians also need to consider the
relative merits of coronary artery bypass graft (CABG) and
PCI in differing patterns of coronary arterial disease to deter-
mine the optimal modality for revascularization. Figure 1 outlines
a simplified approach to patients with CTO in a non-IRA in
patients presenting with STEMI.
While complete revascularization should be attempted in
patients with cardiogenic shock or severe haemodynamic instabil-
ity, no data exist on patients with one or more CTOs in this
setting. In patients with additional complex multivessel disease,
especially if the left main trunk is involved, surgery in the acute
phase might be considered.12 For most patients, pPCI remains
the strategy of choice. If patients remain in shock despite revascu-
larization of the IRA and other non-CTO lesions, a limited attempt
at revascularization of the CTO may be undertaken if adequate
expertise is available. However, several arguments plead against
an aggressive CTO revascularization procedure in this setting.
First, the clinical benefit is uncertain, because no information on
viability or ischaemia in the corresponding territory is available.
Secondly, the armamentarium of techniques and equipment
applied is limited by the clinical presentation. Accordingly addition-
al access for contralateral injection is discouraged to reduce the
amount of contrast injected and minimize vascular complications
in patients that are fully anticoagulated and are frequently
treated with glycoprotein IIb/IIIa receptor inhibitors. In addition,
the use of ‘aggressive’ CTO wires may be associated with increased
risk of perforation due to the profound antithrombosis. As a con-
sequence, the CTO recanalization rates achieved in this setting are
likely to be lower than the 60% reported in a recent multicentre
registry.13
In the absence of shock, the indication for non-IRA CTO reca-
nalization should be reassessed following the acute phase. Patients
with large territory ischaemia or symptoms despite maximal
medical therapy should be considered for revascularization. The
decision regarding the mode of revascularization should be based
on the severity, distribution, and angiographic complexity of the
non-IRA coronary artery disease as well as the type of stents
implanted in the acute phase (drug-eluting or bare metal stents).
A heart team approach including cardiologists and cardiac surgeons
is recommended to optimize the revascularization modality for an
individual patient.14,15 The ongoing Evaluating XIENCE V and LV in
PCI on occlusions after STEMI (EXPLORE) trial investigating
whether PCI of a CTO in a non-IRA within 1 week after primary
PCI has a beneficial effect on LV dimensions and function will
provide additional insight into the role of non-IRA CTO
Figure 1 Simplified approach to chronic total occlusions in a non-infarct-related artery in patients presenting with ST-segment elevation
myocardial infarction. CTO, chronic total occlusion; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery;
SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; VD, vessel disease.
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revascularization. Future randomized studies should incorporate
residual viability and ischaemia assessment in the decision
process and assess clinical endpoints such as survival, myocardial
infarction, and freedom from heart failure hospitalization.
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